世界のインフルエンザワクチン市場動向

◆英語タイトル:Global Influenza Vaccine Market Outlook 2020
◆商品コード:RNCOS5042103
◆発行会社(リサーチ会社):RNCOS
◆発行日:2015年4月
◆ページ数:90
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,100 ⇒換算¥222,600見積依頼/購入/質問フォーム
Multi-User(全社内共有可)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market.

In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, i.e., 2014-2020.

Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population.

In our report “Global Influenza Vaccine Market Outlook 2020”, we have segmented the global influenza vaccine market based on the major vaccine in the market and volume and value sales for each vaccine have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the influenza vaccines already in Phase III trials.

In the end, various key players have been enlisted. Our team has analyzed each company’s financial performance along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Influenza Vaccine – Introduction
4. Global Influenza Vaccine Market Outlook 2020
4.1 Current Market Overview and Future Outlook
4.2 Major Marketed Vaccines
4.2.1 Fluzone/Vaxigrip
4.2.2 FluMist
4.2.3 Fluarix and Flulaval
4.2.4 Anflu
4.2.5 Fluvax/Afluria
4.2.6 Flucelvax and Fluvirin
5. Key Geographical Market
5.1 US
5.2 Europe
5.3 Emerging Markets
5.3.1 China
5.3.2 India
5.4 Rest of the World
5.4.1 Australia
5.4.2 Japan
6. Global Influenza Vaccine Market: Pipeline Analysis
7. Global Influenza Vaccine Market: Pricing Analysis
8. Competitive Assessment
8.1 Sanofi
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 Influenza Vaccine Business
8.2 GlaxoSmithKline Plc (GSK)
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Influenza Vaccine Business
8.3 CSL Ltd
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Influenza Vaccine Business
8.4 AstraZeneca Plc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Influenza Vaccine Business
8.5 Sinovac Biotech
8.5.1 Business Overview
8.5.2 Financial Overview
8.5.3 Influenza Vaccine Business
8.6 Serum Institute of India
8.6.1 Business Overview
8.6.2 Influenza Vaccine Business

List of Figures:

Figure 4-1: Global – Production Capacity and Production of Influenza Vaccine (Million Doses), 2009 & 2011
Figure 4-2: Global – Influenza Vaccine Sales (Million Doses), 2014 & 2020
Figure 4-3: Global – Influenza Vaccine Market (Billion US$), 2014-2020
Figure 4-4: Global – Influenza Vaccine Market by Players (%), 2014
Figure 4-5: Global – Fluzone/Vaxigrip Sales (Million US$), 2010-2014
Figure 4-6: Global – FluMist Sales (Million US$), 2010-2014
Figure 4-7: Global – Fluarix and FluLaval Sales (Million US$), 2010-2014
Figure 4-8: Global – Anflu Sales (Million Doses), 2010-2013
Figure 4-9: Global – Anflu Sales (Million Doses), 2010-2013
Figure 4-10: Global – Afluria/Fluvax Sales (Million US$), 2012-2014
Figure 4-11: Global – Flucevax and Fluvirin Sales (Million US$), 2012-2014
Figure 5-1: Global – Influenza Vaccine Market by Region (%), 2014
Figure 5-2: US – Influenza Vaccine Sales (Million Doses), 2009-10 to 2014-15
Figure 5-3: US – Influenza Vaccine Market by Players (%), 2014
Figure 5-4: US – Influenza Vaccine Market (Billion US$), 2014-2020
Figure 5-5: Europe – Influenza Vaccine Market by Players (%), 2014
Figure 5-6: Europe – Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-7: Europe – Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
Figure 5-8: Emerging Markets – Influenza Vaccine Market by Players (%), 2014
Figure 5-9: Emerging Markets – Influenza Vaccine Market (Million US$), 2014-2020
Figure 5-10: Rest of the World – Influenza Vaccine Market (Million US$), 2014-2020
Figure 8-1: Sanofi – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-2: Sanofi Pasteur – Breakup of Vaccine Segment by Type (%), 2014
Figure 8-3: Sanofi Pasteur – Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-4: GlaxoSmithKline Plc – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-5: GlaxoSmithKline Plc – Breakup of Vaccine Segment by Type (%), 2014
Figure 8-6: GlaxoSmithKline Plc – Breakup of Total Influenza Vaccine Revenue by Geography (%), 2014
Figure 8-7: CSL Ltd – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-8: CSL Ltd – Breakup of bioCSL Revenues by Product Type (%), 2014
Figure 8-9: AstraZeneca Plc – Breakup of Total Revenues by Business Segment (%), 2014
Figure 8-10: AstraZeneca Plc – Breakup of Infection Segment by Type (%), 2014
Figure 8-11: AstraZeneca Plc – Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
Figure 8-12: Sinovac Biotech – Breakup of Vaccine by Type (%), 2013

List of Tables:

Table 5-1: US – Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-2: Percentage of People in the US Who Received Influenza Vaccine (2013-14)
Table 5-3: Number of Pediatric Deaths in US Flu Season (2005-06 to 2014-15)
Table 5-4: US – Seasonal Influenza Vaccination Coverage by Group (%), 2011-12 to 2013-14
Table 5-5: Europe – Major Influenza Vaccines & Manufacturers (2014-15)
Table 5-6: China – Vaccine Classification
Table 5-7: Australia – Major Influenza Vaccines & Manufacturer (2014-15)
Table 6-1: Influenza Vaccine – Pipeline Analysis, 2014
Table 7-1: Major Influenza Vaccines Cost/Dose (US$) for 2015-16 Season
Table 8-1: Sanofi – Key Financials (Million US$), 2012-2014
Table 8-2: Influenza Vaccines Offered by Sanofi Pasteur (2014)
Table 8-3: GlaxoSmithKline Plc – Key Financials (Million US$), 2012-2014
Table 8-4: Influenza Vaccines Offered by GlaxoSmithKline Plc (2014)
Table 8-5: CSL Ltd. – Key Financials (Million US$), 2012-2014
Table 8-6: CSL Influenza Vaccine Portfolio before Merger
Table 8-7: CSL Influenza Vaccine Portfolio after Merger
Table 8-8: AstraZeneca Plc – Key Financials (Million US$), 2012-2014
Table 8-9: Influenza Vaccines Offered by AstraZeneca Plc (2014)
Table 8-10: Sinovac Biotech – Key Financials (Million US$), 2011-2013
Table 8-11: Influenza Vaccines Offered by Sinovac Biotech (2014)



【レポートのキーワード】

インフルエンザワクチン、市販薬、インフルエンザ治療

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のインフルエンザワクチン市場動向(Global Influenza Vaccine Market Outlook 2020)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆